Skip to main content

Key Product Details

Validated by

Knockout/Knockdown

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Knockdown Validated, Western Blot

Cited:

Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # CV5.1

Format

BSA Free

Concentration

1 mg/ml

Product Specifications

Immunogen

His-tagged denatured FANCM (aa 1507-1679) made in E.coli

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Scientific Data Images for FANCM Antibody (CV5.1) - BSA Free

Knockdown Validated: FANCM Antibody (CV5.1) - BSA Free [NBP2-50418]

Knockdown Validated: FANCM Antibody (CV5.1) - BSA Free [NBP2-50418]

Knockdown Validated: FANCM Antibody (CV5.1) [NBP2-50418] - Western blots of FANCM in the POI family. HEK293 cell transfected with a FANCM-specific siRNA were used to validate the specificity of the anti-FANCM antibody. To transiently deplete FANCM, HEK293 cells were transfected with 20 nmol/L of small interfering RNA (siRNA) targeting FANCM, 5'-GGC-UAC-GUC-CAG-GAG-CGC-3' with the CaCL2 method. Panel present the result of a representative experiment on at least three independent analysis. Image collected and cropped by CiteAb from the following publication (https://elifesciences.org/articles/30490) licensed under a CC-BY license.
Immunohistochemistry: FANCM Antibody (CV5.1) - BSA Free [NBP2-50418]

Immunohistochemistry: FANCM Antibody (CV5.1) - BSA Free [NBP2-50418]

Immunohistochemistry: FANCM Antibody (CV5.1) [NBP2-50418] - Immunohistochemistry of FANCM in human fetal and adult ovaries. Fetal ovaries at 8 and 22 wpf and adult ovaries were studied. FANCM positive cells appear in yellow/brown color (monoclonal FANCM CV5.1 antibody, Novus Biologicals, Abingdon, UK). Ovarian sections were counterstained with hematoxylin (blue staining). Oo, oogonia; Pa, oocyte at the pachytene stage of meiosis I, D, oocyte at the diplotene stage of meiosis I; Pr, oocyte in primordial follicle. Image collected and cropped by CiteAb from the following publication (https://elifesciences.org/articles/30490) licensed under a CC-BY license.
FANCM Antibody (CV5.1) - BSA Free

Immunohistochemistry: FANCM Antibody (CV5.1) - BSA Free [NBP2-50418] -

FANCM expression in human fetal ovaries.(A) Relative FANCM mRNA abundance was measured by RT-qPCR in human fetal ovaries from 5 to 32 weeks post-fertilization (wpf). (B) Germ cells (D2-40+) & somatic cells (D2-40-) were sorted from three ovaries ranging from 8 to 12 wpf & FANCM expression was measured. ACTB was used to normalize FANCM expression in all samples. Dots represent different ovaries & the mean is indicated by the line. (C) Immunohistochemistry of FANCM in human fetal & adult ovaries. Fetal ovaries at 8 & 22 wpf & adult ovaries were studied. FANCM positive cells appear in yellow/brown color (monoclonal FANCM CV5.1 antibody, Novus Biologicals, Abingdon, UK). Ovarian sections were counterstained with hematoxylin (blue staining). Oo, oogonia; Pa, oocyte at the pachytene stage of meiosis I, D, oocyte at the diplotene stage of meiosis I; Pr, oocyte in primordial follicle. (D) Co-staining in 22 wpf ovaries, for FANCM (purple) & DDX4 (brown) confirmed the germ cell identity of FANCM-positive cells (left). Successive staining for FANCM & SYCP3 in the same section (panels a & b). Negative control performed with non-immune mouse IgG (right). Scale bar: 10 μm. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29231814), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for FANCM Antibody (CV5.1) - BSA Free

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:100

Immunoprecipitation

2 - 4 ug/ml lysate

Western Blot

1:1000
Application Notes
Positive control(s): 293 cell extract. Use in Immunohistochemistry-paraffin reported in scientific literature (PMID: 29231814).
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 1 review rated 4 using NBP2-50418 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: FANCM

The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group M. [provided by RefSeq]

Alternate Names

ATP-dependent RNA helicase FANCM, EC 3.6.1, FAAP250EC 3.6.4.13, Fanconi anemia, complementation group M, Fanconi anemia-associated polypeptide of 250 kDa, KIAA1596Fanconi anemia group M protein, MGC176453, Protein FACM, Protein Hef ortholog

Gene Symbol

FANCM

Additional FANCM Products

Product Documents for FANCM Antibody (CV5.1) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for FANCM Antibody (CV5.1) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...